Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × INDUSTRY × darolutamide × Clear all

Phase

Status

Completed 15 Recruiting 13 Not yet recruiting 2 Active not recruiting 2 Terminated 1

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1

Interventions

pembrolizumab 146 Paclitaxel 104 Carboplatin 103 Gemcitabine 99 Docetaxel 85 Cyclophosphamide 77 Nivolumab 69 Cisplatin 68 Rituximab 61 Dexamethasone 52 Bevacizumab 51 Pemetrexed 49 Capecitabine 46 fludarabine 44 Azacitidine 42 Fluorouracil 41 venetoclax 40 atezolizumab 39 Irinotecan 35 Trastuzumab 34 130-nm albumin-bound paclitaxel 31 Cetuximab 30 Leucovorin 29 Cytarabine 29 Erlotinib Hydrochloride 28 Oxaliplatin 26 Doxorubicin 26 avelumab 25 Ipilimumab 25 Fulvestrant 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04157088 2023-08-04

DaroAcT

Bayer

Phase 2 Terminated

30 enrolled 25 charts

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡